ER+ breast cancer
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
ER+ breast cancer
Jun 14, 2024, 09:30 |
Blog
Upcoming webinar on "Overcoming Resistance" led by Michael Wick - The START Center for Cancer Research
The START Center for Cancer Research shared on LinkedIn: . "Don't miss our…
Jun 14, 2024, 03:24 |
Blog
Guilherme Nader Marta: Our Review On the PI3K/Akt-targeted Agents
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on X: “PI3K/Akt-targeted agents entered…
Jun 9, 2024, 16:20 |
Insight
Sheheryar Kabraji: Look at how ER low tumors behave
Sheheryar Kabraji, Associate Professor at Roswell Park Comprehensive Cancer Center, shared on X/Twitter: "! Very cool…
Jun 9, 2024, 15:55 |
Insight
Chandler Park: Giuseppe Curigliano on sequencing 1st line and beyond Stage IV ER+ breast cancer
Chandler Park recently shared on LinkedIn: “How to sequence treatments for 1st line and beyond…
Apr 3, 2024, 13:35 |
Insight
Kefah Mokbel: Insights into the management of Leptomeningeal Disease and clinical outcomes
Kefah Mokbel, Chair of The Multidisciplinary Breast Cancer Program at London Breast Institute, shared on…
All:
5
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube